Homeopathy is based on four heterodox and complementary scientific assumptions.

Pseudoskeptics deny these assumptions and any scientific evidence that proves them.

The e-book proves the scientific evidence for homeopathy.

The e-book describes hundreds of experimental and clinical studies in homeopathy.

The e-book demystifies the fallacy that “homeopathy is placebo effect”.

Sexual dysfunction is a common side effect of antidepressants, especially in women.

Identifying effective pharmacological treatments for Antidepressant-Induced Sexual Dysfunction (AISD) is crucial for enhancing patient quality of life.

Bupropion at a dose of 150 mg has shown greater effectiveness in treating AISD in women.

The meta-analysis found no direct correlation between improvements in sexual function and reductions in depressive symptoms.

Homeopathy is based on heterodox and complementary four scientific assumptions.

Pseudosceptics deny these assumptions and any scientific evidence that proves them.

The dossier describes hundreds of clinical and experimental studies in homeopathy.

The dossier demystifies the fallacy that “there isn't scientific evidence for homeopathy”.

Homeopathy employs the principle of therapeutic similitude as a method of treatment.

Primary action of drugs is followed by secondary and opposite reaction of the organism.

This secondary and opposite reaction of the organism is namely the rebound effect of drugs.

Homeopathy employs the rebound effect of drugs in a therapeutic way.

Molecular and IHC markers aid in objective classification and outcome prediction of PT.

Surgery is the gold standard for PT, but margin extent lacks consensus.

Local recurrence is key in PT prognosis, with margin status as the main risk factor.

Adjuvant radiotherapy lowers recurrence in borderline/malignant PTs with close margins.

14 antidepressants show a significant seizure risk association in the FAERS analysis.

Bupropion shows the strongest seizure signal with the highest reporting odds ratio.

TCAs/tetracyclics elevate seizure risk, particularly clomipramine and maprotiline.

SSRIs/SNRIs require safety reconsideration as seizure risk persists.

Mirtazapine is linked to seizure risk despite low initial reports.